CASi-MAPT

CASi-MAPT (also known as CASi-002) is a preclinical-stage siRNA therapeutic being developed by Switch Therapeutics for the treatment of tauopathies, including Alzheimer's disease, frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). The drug utilizes Switch's proprietary Conditionally Activated siRNA (CASi) platform, which consists of novel three-stranded RNA molecules designed for cell-selective knockdown and self-delivery to the central nervous system (CNS). By targeting the MAPT gene (microtubule-associated protein tau) through RNA interference (RNAi), CASi-MAPT aims to reduce the production of intracellular tau protein, thereby addressing the underlying pathology of various neurodegenerative diseases. The CASi platform is designed to combine the attributes of antisense oligonucleotides and siRNAs to enable effective delivery and activity within the CNS.